TIDMAGL
RNS Number : 7938Z
Angle PLC
23 September 2020
For immediate release 23 September 2020
ANGLE plc ("the Company")
BREAKTHROUGH Research using the parsortix system highlights the
potential for new cancer treatment strategy to limit metastasis
Published research using the Parsortix system to isolate CTC
clusters from blood confirms the role of intra-tumour hypoxia in
promoting metastatic breast cancer
Study highlights the potential for Parsortix liquid biopsy in
cancer drug discovery
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company, is delighted to announce that the University of Basel has
published breakthrough research, using ANGLE's Parsortix(R) system,
into the role of hypoxia (reduced oxygen levels) in promoting
breast cancer metastasis.
Groups of circulating tumour cells (CTCs), known as clusters,
have been reported to be 50 times more likely to generate
metastasis compared to individual CTCs. The new research, led by
Professor Nicola Aceto at the Cancer Metastasis Laboratory,
University of Basel Switzerland, found that intra-tumour hypoxia
increased CTC cluster shedding rate and metastasis formation in
mice. In addition, hypoxic (compared to normoxic) CTCs formed
significantly larger cell clusters, leading to the development of
metastasis earlier and reducing survival time.
The new research suggests that intra-tumour hypoxia creates
conditions that stimulate the formation of an increased number and
size of CTC clusters, which may increase (rather than decrease) the
metastatic spread of the cancer. This is critical because over 90%
of patients who die of cancer die of the metastatic spread of the
disease, not because of the primary tumour. In short, it is
possible that some established treatments, whilst they may reduce
growth of the primary tumour short-term, may actually be promoting
the metastatic growth of the cancer, damaging the long-term
outcome. More research will be needed to understand these impacts
and the Parsortix system is the leading system to enable effective
investigation of CTC clusters to facilitate this research.
The researchers also investigated alternative treatments seeking
to reduce the metastatic spread of the disease in breast cancer.
Hypoxia is known to occur in the central core of tumours and within
regions that are poorly vascularised. By using a targeted protein,
EphrinB2, the researchers could increase and normalise
vascularisation in a mouse model, reducing intra-tumour hypoxia.
EprinB2, or other therapies which effect a similar response, could
form the basis of a new treatment strategy for metastatic breast
cancer, both to prevent further metastasis by reducing tumour
hypoxia and shedding of hypoxic CTC clusters, and by increasing
blood flow to allow co-administered chemotherapy agents to better
reach the tumour.
This study demonstrates key capabilities of the Parsortix system
to support cancer drug discovery. It also exemplifies the utility
of the Parsortix system in isolating metastatic breast cancer CTCs,
which is the area of focus for ANGLE's FDA De Novo Submission.
The research, which has been published in the peer-reviewed
journal Cell Reports , may be accessed via
https://angleplc.com/library/publications/ .
Breast cancer is the most frequently diagnosed cancer in women
in the United States and there are an estimated 3.6 million women
living with breast cancer in the United States. Despite new
treatment options and advances in patient management protocols, 30%
of women initially diagnosed with earlier stages of breast cancer
eventually develop recurrent advanced or metastatic disease.
Although the prognosis of patients with metastatic breast cancer
has significantly improved over the last two decades, it remains
largely incurable with median survival of three years.
Approximately 50% of metastatic breast cancer patients are
unable to receive a successful tissue biopsy of the metastatic site
due to the patient being too ill, or problems accessing the
metastatic sites such as the lung, liver, brain and bone, or
insufficient cells being retrieved for analysis. CTCs as a liquid
biopsy, provides for non-invasive, real-time monitoring of cancer
patients, giving comprehensive insight into clonal evolution during
tumour metastasis and the potential to provide actionable
information for targeted therapy.
Professor Nicola Aceto, Group Leader - Cancer Metastasis
Laboratory, University of Basel and University Hospital Basel,
Switzerland, commented:
"Our study suggests that intra-tumour hypoxia is the main
trigger for the generation of hypoxic CTC clusters with a high
tendency to initiate metastasis. We propose that a therapy that
normalises vascularisation may suppress intra-tumour hypoxia and
intravasation of clustered CTCs, leading to a reduction in
metastasis. In combination with other established anti-cancer
agents, Ephrin may not only prevent further metastasis to
metastasis dissemination but also improve perfusion to existing
cancerous lesions, thereby facilitating the uptake of the
co-administered compound. Clinical studies in well-defined patient
populations will be key to address this treatment approach."
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"This study further exemplifies the capability of the Parsortix
system to isolate viable CTCs and CTC clusters, which enable cell
culture and xenograft to further our understanding of tumour cell
biology and metastatic development. This seminal work, by one of
ANGLE's leading customers, exemplifies how the Parsortix system can
enable drug discovery by identifying mechanisms for metastatic
spread which can form the basis of new treatment strategies."
For further information ANGLE:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
finnCap Ltd (NOMAD and Joint Broker)
Corporate Finance - Carl Holmes, Simon
Hicks, Max Bullen-Smith
ECM - Alice Lane, Sunila de Silva +44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes, Nigel Birks, Andrew Craig,
Chris Lee +44 (0) 203 705 9330
FTI Consulting
Simon Conway, Ciara Martin +44 (0) 203 727 1000
Matthew Ventimiglia (US) +1 (212) 850 5624
The information communicated in this announcement is inside
information for the purposes of Article 7 of Regulation
596/2015.
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world leading liquid biopsy company with
sample-to-answer solutions. ANGLE's proven patent protected
platforms include a circulating tumor cell (CTC) harvesting
technology and a downstream analysis system for cost effective,
highly multiplexed analysis of nucleic acids and proteins.
ANGLE's cell separation technology is called the Parsortix(R)
system, and it enables a liquid biopsy (a simple blood test) to be
used to provide the cells of interest to the user in a format
suitable for multiple types of downstream analyses. The system is
based on a microfluidic device that captures cells based on a
combination of their size and compressibility. The system is
epitope independent and can capture all types of CTCs as well as
CTC clusters in a viable form (alive). CTCs enable the complete
picture of a cancer to be seen as being a complete cell they allow
DNA, RNA and protein analysis and the live cells harvested can be
cultured. The Parsortix technology is the subject of 24 granted
patents in Europe, the United States, China, Australia, Canada,
India, Japan and Mexico with three extensive families of patents
are being progressed worldwide. The Parsortix system has a CE Mark
in Europe for the indicated use and FDA clearance is in process for
the United States with a 400 subject clinical study and associated
analytical studies in metastatic breast cancer. ANGLE is seeking to
be the first ever FDA cleared CTC harvesting system and only the
third ever FDA cleared liquid biopsy test. ANGLE has already
undertaken two separate 200 subject clinical studies under a
program designed to develop an ovarian cancer pelvic mass triage
test, with the results showing best in class accuracy (ROC-AUC) of
95.1%. The pelvic mass triage assay has undergone further
refinement and optimisation, and is currently in the process of a
200 patient clinical verification study.
ANGLE's technology for the multiplex evaluation of proteins and
nucleic acids of all types is called the HyCEADTM Ziplex(R)
platform and is based on a patented flow through array technology.
It provides for low cost, highly multiplexed, rapid and sensitive
capture of targets from a wide variety of sample types. A
proprietary chemistry approach (the HyCEAD method) allows for the
capture and amplification of over 100 biomarkers simultaneously in
a single reaction. The HyCEAD Ziplex system is extremely sensitive
and is ideal for measuring gene expression and other markers
directly from Parsortix harvests and was used in the ovarian cancer
pelvic mass triage test to achieve best in class accuracy (ROC-AUC)
of 95.1%.
ANGLE's proprietary technologies can be combined to provide
automated, sample-to-answer results in both centralised laboratory
and point-of-use cartridge formats.
ANGLE has established formal collaborations with world-class
cancer centres and major corporates such as Abbott, Philips and
QIAGEN, and works closely with leading CTC translational research
customers. These Key Opinion Leaders (KOLs) are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. The body of evidence as to the benefits of the Parsortix
system is growing rapidly from our own clinical studies in
metastatic breast cancer and ovarian cancer and also from KOLs with
36 peer-reviewed publications and numerous publicly available
posters, available on our website.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCKZGZLLZNGGZM
(END) Dow Jones Newswires
September 23, 2020 02:00 ET (06:00 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2024 to May 2024
Angle (LSE:AGL)
Historical Stock Chart
From May 2023 to May 2024